Hospice Valuation & Sale Process
Hospice attracts strong buyer interest and high regulatory scrutiny in equal measure. Value comes from defensible compliance, clean documentation, stable census economics, and a clear story a buyer can underwrite. The first step is knowing your number, and what would move it.
Free valuation calculator What moves your number Jump to FAQs
No upfront fee. No obligation. Success-based, confidentiality-first advisory.
Why is hospice valuation different right now?
Hospice valuation is different because buyers underwrite program integrity as closely as earnings. With heightened oversight across the sector, the agencies that command premium multiples are the ones whose documentation, length-of-stay profile, and quality signals tell a clean, defensible story.
As of June 2026, most well-run hospices trade in the 5.0x to 9.0x EBITDA range, with premium platforms reaching 10x to 15x and smaller agencies lower. M&A has reopened, helped by steadier reimbursement after the CMS FY2026 update of plus 2.6 percent and an aggregate cap of $35,361.44, and buyers have tightened add-backs from roughly 20 percent to 15 to 25 percent. These are ranges, not promises, and clean documentation now defends your number.
Documentation
Complete, defensible clinical and eligibility documentation is the first thing a buyer tests, and the fastest way to protect your multiple.
Length of stay + mix
A balanced length-of-stay profile and diagnosis mix signal sustainable census economics rather than cap or audit risk.
Quality signals
Survey history, CAHPS scores, and the new HOPE assessment data give buyers confidence in the quality of care.
What do buyers look for in a hospice acquisition?
Buyers look for a hospice they can underwrite with confidence, where compliance is clean and census economics are sustainable. The most active acquirers are private-equity-backed platforms, regional strategics, and larger hospices expanding their footprint.
- Defensible documentation — eligibility, certification, and clinical records that withstand audit and diligence.
- A balanced length-of-stay and diagnosis mix — census economics that are not exposed to the aggregate cap.
- Strong quality signals — survey history, CAHPS, and HOPE-era quality data.
- A clean program-integrity record — minimal regulatory exposure and a credible compliance program.
- Diversified referral sources — admissions that are not concentrated in one facility or physician.
- Defensible adjusted EBITDA — add-backs that hold up under 2026 diligence standards.
What drives a hospice's valuation multiple?
The multiple a buyer applies reflects how defensible and sustainable your program is. These are the levers that move it most, and most can be strengthened in the 12 months before you go to market.
| Value driver | Effect on multiple | Why buyers care |
|---|---|---|
| Defensible documentation and compliance | Raises | Lower audit and program-integrity risk |
| Balanced length of stay and diagnosis mix | Raises | Sustainable census economics, low cap exposure |
| Strong quality signals and referrals | Raises | Confidence in care quality and admissions |
| Documentation gaps or cap exposure | Lowers | Surfaces as risk and lost add-backs in diligence |
| Referral concentration in one source | Lowers | Admissions may move if that source changes |
Directional effect on hospice multiples, as of mid-2026. Sources: FOCUS Investment Banking, 2026; Hospice News, 2026; CMS FY2026 Hospice Wage Index Final Rule. The HOPE assessment tool took effect October 1, 2025.
How do you sell a hospice the clean way?
A confidential process typically runs 6 to 9 months from valuation to close. Because hospice diligence is documentation-heavy, starting 12 months ahead to map and close any risk is what protects value.
Baseline + risk map
We rebuild adjusted EBITDA, map documentation, length-of-stay, and compliance risk, and target the levers that lift your multiple.
Confidential marketing
We approach qualified buyers behind NDAs, protecting your staff, referral sources, and families while creating competition.
Diligence + close
We manage clinical and financial diligence, defend your documentation, negotiate terms, and guide the transition so value holds.
What should hospice owners know about the market?
Hospice M&A has come back. Q4 2025 was the strongest hospice quarter in four years and deal volume is running at its highest since 2021, with private-equity capital back at the table and steadier reimbursement after the CMS FY2026 update. The catch is discipline: buyers now defend their offers with documentation, so preparation directly protects your number.
typical hospice EBITDA range (premium platforms 10x–15x)
CMS FY2026 payment update; aggregate cap now $35,361.44
EBITDA add-backs buyers now accept, down from about 20%
Sources: CMS FY2026 Hospice Wage Index Final Rule; Hospice News, May 2026; FOCUS Investment Banking, 2026; Mertz Taggart, 2026.
See where your hospice stands
Start with a confidential estimate, then test the number against live buyer demand. A valuation is a planning tool. It commits you to nothing.
No upfront fee. No obligation.
Resources to go deeper
Hospice valuation & selling FAQs
How is hospice valuation calculated?
Hospice valuation is calculated by normalizing earnings into adjusted EBITDA, applying a market multiple for your size and profile, and adjusting for the factors a buyer tests in diligence, chiefly documentation quality, length-of-stay and diagnosis mix, compliance history, and referral concentration. As of June 2026 most well-run hospices trade in the 5.0x to 9.0x EBITDA range.
What is a hospice multiple?
A hospice multiple is the number applied to adjusted EBITDA to estimate enterprise value. In 2026 most well-run hospices trade at 9.0x to 12.5x EBITDA, premium platforms reach 15x to 25x, and smaller or higher-risk agencies trade lower. The multiple is mostly a measure of how defensible and transferable your earnings are.
Can I sell my Medicare hospice?
Yes. Medicare-certified hospices are sold regularly, and the certification and provider agreement are central to the transaction. Buyers will examine eligibility documentation, the aggregate cap position, and compliance history closely, which is why clean records are the most important preparation you can do.
How does the aggregate cap affect my hospice's value?
The aggregate cap limits total Medicare payment per beneficiary, so an agency with a long average length of stay can face cap liability that a buyer treats as risk. A balanced length-of-stay and diagnosis mix that keeps you comfortably under the cap supports a higher multiple.
What are the steps to sell a hospice?
The clean path is a baseline valuation and risk map, then confidential marketing to qualified buyers behind NDAs, then diligence and close. Most owners benefit from starting 12 months ahead so documentation and any compliance gaps are addressed before buyers look.
Will a valuation obligate me to sell?
No. A valuation is confidential and carries no obligation. It is a planning tool that tells you what your hospice is worth today and what would make it worth more, so any future decision is yours to make on your own timeline.
Find out what your hospice is worth
Vallexa Advisors is a healthcare-only M&A firm with deep roots in hospice. We help owners understand value, prepare intelligently, and run a confidential sale process that attracts qualified buyers.
No upfront fee. No obligation. 100% success-based.
Educational only. Not legal, financial, or tax advice. Hospice M&A outcomes depend on specific facts, payer mix, documentation, market conditions, and regulatory context. Speak with qualified counsel before acting on anything on this page.
A Hospice Owner’s Guide to Valuation Multiples: What Drives Price, How to Prepare, and How to Avoid Exit Pitfalls (U.S.)
Hospice Valuation: Understanding the Process and Maximizing Your Agency’s Worth
Top 10 Questions to Ask an Advisor Before Getting a Hospice Valuation
2026 Hospice & Home Health Valuation Multiples Report (US Market)
Hospice Valuation & Sale Process
Hospice attracts strong buyer interest and high regulatory scrutiny in equal measure. Value comes from defensible compliance, clean documentation, stable census economics, and a clear story a buyer can underwrite. The first step is knowing your number, and what would move it.
Free valuation calculator What moves your number Jump to FAQs
No upfront fee. No obligation. Success-based, confidentiality-first advisory.
Why is hospice valuation different right now?
Hospice valuation is different because buyers underwrite program integrity as closely as earnings. With heightened oversight across the sector, the agencies that command premium multiples are the ones whose documentation, length-of-stay profile, and quality signals tell a clean, defensible story.
As of June 2026, most well-run hospices trade in the 9.0x to 12.5x EBITDA range, with premium platforms reaching 10x to 15x and smaller agencies lower. M&A has reopened, helped by steadier reimbursement after the CMS FY2026 update of plus 2.6 percent and an aggregate cap of $35,361.44, and buyers have tightened add-backs from roughly 20 percent to 12 to 15 percent. These are ranges, not promises, and clean documentation now defends your number.
Documentation
Complete, defensible clinical and eligibility documentation is the first thing a buyer tests, and the fastest way to protect your multiple.
Length of stay + mix
A balanced length-of-stay profile and diagnosis mix signal sustainable census economics rather than cap or audit risk.
Quality signals
Survey history, CAHPS scores, and the new HOPE assessment data give buyers confidence in the quality of care.
What do buyers look for in a hospice acquisition?
Buyers look for a hospice they can underwrite with confidence, where compliance is clean and census economics are sustainable. The most active acquirers are private-equity-backed platforms, regional strategics, and larger hospices expanding their footprint.
- Defensible documentation — eligibility, certification, and clinical records that withstand audit and diligence.
- A balanced length-of-stay and diagnosis mix — census economics that are not exposed to the aggregate cap.
- Strong quality signals — survey history, CAHPS, and HOPE-era quality data.
- A clean program-integrity record — minimal regulatory exposure and a credible compliance program.
- Diversified referral sources — admissions that are not concentrated in one facility or physician.
- Defensible adjusted EBITDA — add-backs that hold up under 2026 diligence standards.
What drives a hospice's valuation multiple?
The multiple a buyer applies reflects how defensible and sustainable your program is. These are the levers that move it most, and most can be strengthened in the 12 months before you go to market.
| Value driver | Effect on multiple | Why buyers care |
|---|---|---|
| Defensible documentation and compliance | Raises | Lower audit and program-integrity risk |
| Balanced length of stay and diagnosis mix | Raises | Sustainable census economics, low cap exposure |
| Strong quality signals and referrals | Raises | Confidence in care quality and admissions |
| Documentation gaps or cap exposure | Lowers | Surfaces as risk and lost add-backs in diligence |
| Referral concentration in one source | Lowers | Admissions may move if that source changes |
Directional effect on hospice multiples, as of mid-2026. Sources: FOCUS Investment Banking, 2026; Hospice News, 2026; CMS FY2026 Hospice Wage Index Final Rule. The HOPE assessment tool took effect October 1, 2025.
How do you sell a hospice the clean way?
A confidential process typically runs 6 to 9 months from valuation to close. Because hospice diligence is documentation-heavy, starting 12 months ahead to map and close any risk is what protects value.
Baseline + risk map
We rebuild adjusted EBITDA, map documentation, length-of-stay, and compliance risk, and target the levers that lift your multiple.
Confidential marketing
We approach qualified buyers behind NDAs, protecting your staff, referral sources, and families while creating competition.
Diligence + close
We manage clinical and financial diligence, defend your documentation, negotiate terms, and guide the transition so value holds.
What should hospice owners know about the market?
Hospice M&A has come back. Q4 2025 was the strongest hospice quarter in four years and deal volume is running at its highest since 2021, with private-equity capital back at the table and steadier reimbursement after the CMS FY2026 update. The catch is discipline: buyers now defend their offers with documentation, so preparation directly protects your number.
typical hospice EBITDA range (premium platforms 10x–15x)
CMS FY2026 payment update; aggregate cap now $35,361.44
EBITDA add-backs buyers now accept, down from about 20%
Sources: CMS FY2026 Hospice Wage Index Final Rule; Hospice News, May 2026; FOCUS Investment Banking, 2026; Mertz Taggart, 2026.
See where your hospice stands
Start with a confidential estimate, then test the number against live buyer demand. A valuation is a planning tool. It commits you to nothing.
No upfront fee. No obligation.
Resources to go deeper
Hospice valuation & selling FAQs
How is hospice valuation calculated?
Hospice valuation is calculated by normalizing earnings into adjusted EBITDA, applying a market multiple for your size and profile, and adjusting for the factors a buyer tests in diligence, chiefly documentation quality, length-of-stay and diagnosis mix, compliance history, and referral concentration. As of June 2026 most well-run hospices trade in the 9.0x to 12.5x EBITDA range.
What is a hospice multiple?
A hospice multiple is the number applied to adjusted EBITDA to estimate enterprise value. In 2026 most well-run hospices trade at 9.0x to 12.5x EBITDA, premium platforms reach 10x to 15x, and smaller or higher-risk agencies trade lower. The multiple is mostly a measure of how defensible and transferable your earnings are.
Can I sell my Medicare hospice?
Yes. Medicare-certified hospices are sold regularly, and the certification and provider agreement are central to the transaction. Buyers will examine eligibility documentation, the aggregate cap position, and compliance history closely, which is why clean records are the most important preparation you can do.
How does the aggregate cap affect my hospice's value?
The aggregate cap limits total Medicare payment per beneficiary, so an agency with a long average length of stay can face cap liability that a buyer treats as risk. A balanced length-of-stay and diagnosis mix that keeps you comfortably under the cap supports a higher multiple.
What are the steps to sell a hospice?
The clean path is a baseline valuation and risk map, then confidential marketing to qualified buyers behind NDAs, then diligence and close. Most owners benefit from starting 12 months ahead so documentation and any compliance gaps are addressed before buyers look.
Will a valuation obligate me to sell?
No. A valuation is confidential and carries no obligation. It is a planning tool that tells you what your hospice is worth today and what would make it worth more, so any future decision is yours to make on your own timeline.
Find out what your hospice is worth
Vallexa Advisors is a healthcare-only M&A firm with deep roots in hospice. We help owners understand value, prepare intelligently, and run a confidential sale process that attracts qualified buyers.
No upfront fee. No obligation. 100% success-based.
Educational only. Not legal, financial, or tax advice. Hospice M&A outcomes depend on specific facts, payer mix, documentation, market conditions, and regulatory context. Speak with qualified counsel before acting on anything on this page.